SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is seeing significant momentum as the SEC eliminates the pattern day trader rule, a move that retail investors believe will drive higher trading volume and brokerage engagement. The community is actively debating the stock's potential for a short squeeze and long-term valuation recovery following the termination of previous dilution-heavy financing agreements.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a massive $8 billion order from SK Hynix for next-generation EUV lithography tools, signaling robust long-term demand for AI-driven chip capacity. Community sentiment remains focused on the company's monopolistic position in the semiconductor supply chain, with active discussions weighing this hardware dominance against broader macroeconomic volatility and geopolitical risks affecting the tech sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing heightened volatility and active community debate as investors speculate on semiconductor demand amidst geopolitical uncertainty, with many traders closely monitoring the impact of potential trade escalations and sector-specific supply chain constraints. Discussions remain sharply divided between those playing for a short squeeze or breakout and those hedging against potential downturns, highlighting the stock's role as a high-beta instrument for both momentum bulls and inverse-focused bears.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending as retail investors aggressively pile into the stock following a definitive agreement with Crypto.com to enter the U.S. prediction market space. The community is sharply divided between those calling for a multi-day short squeeze toward triple-digit valuations and skeptics warning that the stock is a classic pump-and-dump setup prone to rapid volatility.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense market volatility driven by a massive, high-short-interest squeeze that has retail and institutional traders debating whether the parabolic run is a sustainable breakout or a looming blow-off top. Community discussion is sharply divided between those chasing the exponential price action and others warning of historical parallels to past meme stock crashes, citing concerns over high RSI levels and potential share dilution.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community attention as it secures defense-focused contracts and advances its neutral-atom technology, with investors closely watching for upcoming financial guidance and potential analyst coverage. While community members discuss the stock's volatility and the long-term potential of quantum sensing to disrupt legacy navigation systems, the prevailing sentiment remains focused on the company's competitive position within the evolving quantum computing sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is seeing a surge in investor interest driven by a significant regulatory shift following the SEC's approval to eliminate the $25,000 minimum equity requirement for day trading, a move the community believes will lower barriers to entry and increase platform activity. Investors are actively debating the long-term bullish implications of this policy change on revenue and retail participation, while others remain focused on technical levels and broader correlations with crypto market momentum.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following a strategic shift to redomicile in the U.S. and provide PFIC reporting clarity, which effectively neutralized a recent activist short report targeting the company's tax status. The community is actively discussing the stock's potential for a short squeeze and institutional re-rating as investors focus on the company's progress in high-speed optical networking and its pivot toward U.S. domestic corporate governance.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining momentum as the community highlights its unique 15-year history as the original Bitcoin parody, framing its recent shift to on-chain status as a long-awaited rediscovery. Investors are actively discussing the project's organic growth and the accumulation by whale wallets, with many proponents viewing the current consolidation phase as a strategic opportunity before broader market recognition.

Mezo is the onchain Bitcoin banking platform owned by its users. Users can access self-service Bitcoin finance without interacting with loan officers, undergoing credit checks, or observing operational hours. It’s just you, your Bitcoin, and permissionless access to financial services 24/7.  Traditional banks profit from your deposits while charging you for access to your own money. Two-sided lending markets trap you with 8-9% variable rates that can spike unpredictably, especially in decentralized financial systems. Both systems put middlemen between you and your wealth.  Mezo eliminates them all, giving you the power to manage your finances intelligently on your own terms.  Deposit Bitcoin as collateral, mint MUSD (a dollar-pegged stablecoin), and use it however you need. Your Bitcoin stays yours while MUSD provides you with instant liquidity. Fixed rates start as low as 1% and stay fixed for the entire life of the loan.  This is self-service banking with complete autonomy. Unlike any traditional banking experience, there are no minimum payments, set repayment schedules, or penalties for early repayment. Close your position tomorrow or keep it open for years.  It’s your Bitcoin and your decision on what to do with it.

MEZO

MEZO is capturing significant attention as a newly listed Bitcoin side-chain token that offers utility in staking, governance, and DeFi through a strategic partnership with Aerodrome Finance. While some community members are optimistic about its long-term potential within the Bitcoin ecosystem, others are actively debating whether the current price action represents a genuine breakout opportunity or a volatile pump-and-dump scenario.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap ETF (SFLO) Hits New 52-Week High

SFLO hits a 52-week high, up about 50% from lows; strong cash flow focus and small-cap resilience may support further near-term upside.

<ul class="summary-bullets"><li>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12.</li><li>The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.</li><li>Wedbush stated that it has “limited conviction and visibility” regarding StubHub’s direct issuance business.</li></ul>StubHub Holdings Inc.’s (STUB) lackluster fourth-quarter (Q4) results drew a spate of downgrades from Wall Street, with analysts pointing to a series of concerns about the company’s future outlook and the regulatory environment.<a href="https://stocktwits.com/symbol/STUB">StubHub shares</a> tumbled more than 14% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Worried?</h2>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12. The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.JPMorgan stated that StubHub’s 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance is now 60% lower than what the company projected in October 2025. The firm said that while the new outlook “may finally be achievable,” it will have to work through the lock-up expiration beginning March 9, 2026, and also overcome ongoing regulatory concerns around the company.Analysts at Wedbush also downgraded StubHub to ‘neutral’ from ‘outperform’ and lowered the price target by 80% to $10 from $18. The firm stated that it has “limited conviction and visibility” in StubHub’s direct issuance business, noting that the ticket resale broker’s management’s “lofty” expectations are not materializing.Wedbush also stated that regulatory risks will remain an overhang on the stock, while adding that the company is vulnerable to AI-enabled disintermediation in the coming years, given that companies operating in the space face the risk from commoditization.<h2 class="st-heading-2">StubHub’s Q4 At A Glance</h2>StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share (EPS) of $0.13 during the same quarter a year ago. Wall Street expected the company to report a loss of $0.02 per share during the quarter, according to Fiscal.ai data.The company’s revenue in Q4 was $449 million, down from $533 million in the year-ago period. Wall Street consensus projected StubHub to report revenue of $485 million during the period.StubHub’s founder and CEO, Eric Baker, remained optimistic about the company’s prospects, stating that 2025 reinforced that the ticket resale broker’s mission is as relevant as ever. “Our full-year performance validates our long-term strategy and the substantial value we're creating for fans, partners, and shareholders alike,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React To STUB?</h2>One user on Stocktwits pointed to macroeconomic challenges in the U.S., adding that the amount of money people have to spend on “luxuries” is declining.<stembedurl>https://stocktwits.com/insanitywolftrading/message/646656600</stembedurl>However, a bullish user said that StubHub is a “solid company with actually great earnings.”<stembedurl>https://stocktwits.com/llevi/message/646632021</stembedurl><a href="https://stocktwits.com/symbol/STUB">STUB stock</a> is down 25% year-to-date and 64% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-stock-soars-q4-beat-palladyne-ai-ceo-touts-deeper-defense-engagement/cZdQqg1RI3P">Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The StubHub logo and webpage are displayed on a cell phone and computer monitor. (Photo Illustration by Mario Tama/Getty Images)

StubHub's Q4 Miss Draws Multiple Downgrades From Wall Street – Analysts Warn Of ‘Credibility’ Gap

StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share of $0.13 during the same quarter a year ago, while Wall Street expected a loss of $0.02 per share.

Equity

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.</li><li>It said that the Wakix franchise delivered net revenue of approximately $239 million in the third quarter.&nbsp;</li></ul>Shares of Harmony Biosciences Holdings (HRMY) jumped 6% in the premarket session on Thursday after the company raised its full-year revenue guidance on strong Wakix sales.The firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251023496242/en/Harmony-Biosciences-Preannounces-Strong-Q3-2025-WAKIX-Performance-Raises-2025-Revenue-Guidance">expects</a> full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.<h2 class="st-heading-2">Excessive Sleepiness Medication Drives Revenue</h2>The company said that its Wakix franchise delivered net revenue of approximately $239 million in the third quarter (Q3), representing 29% year-over-year revenue growth. Wakix is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, causing excessive daytime sleepiness and uncontrollable sleep attacks. Other symptoms include sudden loss of muscle control called cataplexy. The company said the increase in Wakix revenue was driven by higher average patient volume.The company is expected to report full Q3 earnings on November 4.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained at ‘low’ levels.Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">announced</a> that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance due to a higher-than-expected placebo response rate. Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability.CEO Jeffrey M. Dayno then highlighted the company’s strong portfolio, noting that it is on track to initiate late-stage trials of Wakix in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year.HRMY shares are down 24% this year and by about 23% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-nearly-64000-cybertrucks-over-concerns-with-front-parking-lights/cLG4hXGR3AH">Tesla Recalls Nearly 64,000 Cybertrucks Over Concerns With The Front Parking Lights</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?

The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.

Is Now the Time to Buy Small-Cap Stocks?

We discuss the outlook for small-cap stocks and highlight four ETFs.

The Zacks Analyst Blog Highlights MCOW, SCOW, SFLO and CALF

Pacer???s new MCOW and SCOW ETFs spotlight quality small- and mid-cap firms with strong free cash flow, joining rivals SFLO and CALF.

Looking for Quality ETFs in Smaller Caps? Tap 2 New FCF Aristocrats 

MCOW and SCOW debut with quality-focused strategies, targeting mid- and small-cap stocks with strong free cash flow records.



SFLO
Victory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SFLO News

SFLOVictory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF